Brean Capital set a $14.00 target price on Trevena Inc. (NASDAQ:TRVN) in a report issued on Thursday morning. The brokerage currently has a a buy rating on the biopharmaceutical company’s stock.

TRVN has been the topic of several other reports. TheStreet cut Trevena from a hold rating to a sell rating in a research report on Friday, June 17th. Zacks Investment Research cut Trevena from a hold rating to a sell rating in a research report on Tuesday, July 12th. Jefferies Group reaffirmed a buy rating on shares of Trevena in a research report on Friday, August 5th. Cowen and Company reaffirmed a buy rating on shares of Trevena in a research report on Thursday, June 2nd. Finally, FBR & Co reiterated a buy rating and set a $13.00 target price on shares of Trevena in a research note on Thursday, August 4th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and nine have given a buy rating to the company. Trevena presently has an average rating of Buy and an average price target of $14.30.

Trevena (NASDAQ:TRVN) opened at 7.04 on Thursday. The stock has a 50 day moving average price of $6.94 and a 200-day moving average price of $7.30. Trevena has a 12-month low of $5.58 and a 12-month high of $13.10. The company’s market capitalization is $367.33 million.

Trevena (NASDAQ:TRVN) last released its quarterly earnings data on Thursday, August 4th. The biopharmaceutical company reported ($0.37) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.36) by $0.01. Trevena had a negative net margin of 841.00% and a negative return on equity of 45.01%. Equities analysts predict that Trevena will post ($1.55) EPS for the current fiscal year.

Several large investors have recently bought and sold shares of TRVN. Barclays PLC raised its stake in Trevena by 64.0% in the first quarter. Barclays PLC now owns 12,677 shares of the biopharmaceutical company’s stock valued at $101,000 after buying an additional 4,945 shares during the period. Goldman Sachs Group Inc. raised its stake in shares of Trevena by 70.6% in the first quarter. Goldman Sachs Group Inc. now owns 17,680 shares of the biopharmaceutical company’s stock worth $146,000 after buying an additional 7,314 shares during the last quarter. National Planning Corp raised its stake in shares of Trevena by 21.9% in the first quarter. National Planning Corp now owns 19,452 shares of the biopharmaceutical company’s stock worth $151,000 after buying an additional 3,500 shares during the last quarter. Alliancebernstein L.P. acquired a new stake in shares of Trevena during the second quarter worth about $163,000. Finally, Highbridge Capital Management LLC acquired a new stake in shares of Trevena during the second quarter worth about $225,000. Hedge funds and other institutional investors own 75.43% of the company’s stock.

Trevena Company Profile

Trevena Inc is a clinical-stage biopharmaceutical company. The Company discovers, develops and intends to commercialize therapeutics that use an approach to target G protein coupled receptors (GPCRs). Using its product platform, the Company has identified and advanced three differentiated product candidates: Oliceridine (TRV130), TRV027 and TRV250.

5 Day Chart for NASDAQ:TRVN

Receive News & Ratings for Trevena Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trevena Inc. and related companies with MarketBeat.com's FREE daily email newsletter.